Exscientia raises $60 million in Series C financing round led by Novo Holdings

26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, Senior Partner and Head of Novo Growth, the growth equity arm of Novo Holdings, joins Exscientia’s board of directors as part of the financing round.

More ›

RefleXion Medical raises $100m for biology-guided cancer radiotherapy

Public Sector Pension Investment Board (PSP Investments), a large, Canada-based pension investment manager focused on long-term investments, led the funding, according to a news release. Existing investors TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc. all participated in the round. BofA Securities and Morgan Stanley acted as placement agents.

More ›